Etomoxir has already been through [[Phases of clinical research|phase II clinical development]] for the treatment of [[type 2 diabetes]] and [[heart failure]]. Etomoxir went through [[preclinical trial]]s by Byk Gulden laboratories (now [[Altana|Altana Pharma AG]]) from 1981 to 1984.<ref name=":0">{{Cite web|url = http://www.bioscience-beteiligungs-anstalt.com/en/|title = Drug candidates with blockbuster potential|date = 2015|accessdate = 19 March 2015|website = bioscience-beteiligungs-anstalt.com|publisher = BioScience Beteiligungs Anstalt}}</ref> From 1984 to 1993, etomoxir was developed through phase I and II trials that showed favorable effects on the heart and a good safety profile.<ref>{{Cite web|url = http://www.evaluategroup.com/Universal/View.aspx?type=Story&id=10102|title = MediGene AG starts phase 2 clinical trial for its cardiac lead product Etomoxir|date = 12 December 2000|accessdate = 19 March 2015|website = Evaluate|publisher = Evaluate Ltd}}</ref> In 1999, the [[patent]] was out-licensed to [[MediGene]] for further trials.<ref name=":0" /> In 2001, MediGene was granted extended patent rights for the use of etomoxir for the treatment of [[congestive heart failure]].<ref>{{Cite web|url = http://www.evaluategroup.com/Universal/View.aspx?type=Story&id=10110|title = MediGene´s rights for Etomoxir extended to novel indications|date = 15 February 2001|accessdate = 19 March 2015|website = Evaluate Group|publisher = Evaluate Ltd}}</ref> In 2002, MediGene announced that it terminated a phase II trial for the use of etomoxir for heart failure due to adverse [[side effects]].<ref>{{Cite web|url = http://www.evaluategroup.com/Universal/View.aspx?type=Story&id=24873|title = MediGene’s Etomoxir project delayed|date = 19 April 2002|accessdate = 19 March 2015|website = Evaluate Group|publisher = Evaluate Ltd}}</ref> MediGene funded a study of etomoxir as a treatment of heart failure in 2007, but the study was once again terminated prematurely. Four of the 226 patients taking the drug showed unacceptably high liver [[transaminase]] levels, which was determined by the experimenters to likely be due to the treatment.<ref name="pmid17319797">{{cite journal|vauthors=Holubarsch CJ, Rohrbach M, Karrasch M, Boehm E, Polonski L, Ponikowski P | title=A double-blind randomized multicentre clinical trial to evaluate the efficacy and safety of two doses of etomoxir in comparison with placebo in patients with moderate congestive heart failure: the ERGO (etomoxir for the recovery of glucose oxidation) study. | journal=Clin Sci (Lond) | year= 2007 | volume= 113 | issue= 4 | pages= 205–12 | pmid=17319797 | doi=10.1042/CS20060307 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=17319797  |display-authors=etal}}</ref> The [[University of Colorado]] currently holds patents for the use of etomoxir as an [[anti-inflammatory]] and [[anticarcinogenic]] agent.<ref>Newell, Martha K., Evan Newell, and Elizabeth Villobos-Menvey. [http://www.google.com/patents/US7510710 Etomoxir and a 2-deoxy-D-glucose Compound; Antiinflammatory, Antiproliferative, Anticarcinogenic and Wound Healing Agents; Drug Resistant Cancers]. The Regents Of The University Of Colorado, assignee. Patent US7510710 B2. 31 Mar. 2009.</ref> However, the clinical development of etomoxir has been terminated due to severe [[hepatotoxicity]] associated with treatment.<ref name="pmid24113830">{{cite journal|vauthors=Galluzzi L, Kepp O, Vander Heiden MG, Kroemer G | title=Metabolic targets for cancer therapy. | journal=Nat Rev Drug Discov | year= 2013 | volume= 12 | issue= 11 | pages= 829–46 | pmid=24113830 | doi=10.1038/nrd4145 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=24113830  }}</ref>
